Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Jane Street Group LLC

Jane Street Group LLC lowered its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 42.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,514 shares of the company’s stock after selling 11,240 shares during the period. Jane Street Group LLC’s holdings in Entrada Therapeutics were worth $248,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TRDA. Janus Henderson Group PLC raised its position in shares of Entrada Therapeutics by 10.5% in the third quarter. Janus Henderson Group PLC now owns 1,711,459 shares of the company’s stock valued at $27,358,000 after buying an additional 161,962 shares during the last quarter. State Street Corp raised its position in shares of Entrada Therapeutics by 5.5% in the third quarter. State Street Corp now owns 469,601 shares of the company’s stock valued at $7,504,000 after buying an additional 24,385 shares during the last quarter. American Century Companies Inc. raised its position in shares of Entrada Therapeutics by 5.1% in the second quarter. American Century Companies Inc. now owns 384,973 shares of the company’s stock valued at $5,486,000 after buying an additional 18,625 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in shares of Entrada Therapeutics by 50.3% in the third quarter. Jacobs Levy Equity Management Inc. now owns 201,803 shares of the company’s stock valued at $3,225,000 after buying an additional 67,559 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Entrada Therapeutics by 14.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 185,984 shares of the company’s stock valued at $2,972,000 after buying an additional 23,643 shares during the last quarter. Institutional investors and hedge funds own 86.39% of the company’s stock.

Entrada Therapeutics Stock Performance

Shares of TRDA stock opened at $14.65 on Friday. Entrada Therapeutics, Inc. has a one year low of $11.35 and a one year high of $21.79. The company has a 50 day moving average price of $18.50 and a 200 day moving average price of $16.88. The firm has a market capitalization of $548.20 million, a price-to-earnings ratio of 9.21 and a beta of -0.12.

Insider Buying and Selling

In other Entrada Therapeutics news, insider Natarajan Sethuraman sold 1,409 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $20.01, for a total transaction of $28,194.09. Following the completion of the sale, the insider now directly owns 163,588 shares in the company, valued at $3,273,395.88. The trade was a 0.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Kory James Wentworth sold 8,637 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $19.98, for a total transaction of $172,567.26. Following the sale, the chief financial officer now owns 73,849 shares of the company’s stock, valued at approximately $1,475,503.02. This represents a 10.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 42,281 shares of company stock valued at $861,999. Insiders own 7.59% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Roth Mkm assumed coverage on shares of Entrada Therapeutics in a research report on Thursday, December 5th. They issued a “buy” rating and a $29.00 price objective for the company. HC Wainwright boosted their price objective on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Oppenheimer boosted their price objective on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a research report on Wednesday, November 6th. Finally, Roth Capital raised shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.